ARYD News and Press, ARYA Sciences Acquisition Corp IV

2024-07-18 02:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-06-07 20:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, announces that ...

2024-02-14 09:13:38 ET More on ARYA Sciences Acquisition Corp IV Financial information for ARYA Sciences Acquisition Corp IV Read the full article on Seeking Alpha For further details see: Adagio Medical to go public in $113M deal with SPAC ARYA Sciences

Adagio Medical To List on Nasdaq Through Business Combination with ARYA Sciences Acquisition Corp IV, Enabling Further Commercial and Clinical Development of Innovative Cardiac Ablation Technologies PR Newswire Combined Company expects to receive approximately $42 million ...

2024-01-04 07:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

NEW YORK, July 03, 2023 (GLOBE NEWSWIRE) -- ARYA Sciences Acquisition Corp V (the “Company”) (Nasdaq: ARYE), a special purpose acquisition company, today announced that as of the close of business on July 14, 2023, the Company’s publicly held Class A ordinary shares...

ARYA Sciences Acquisition Corp IV (NASDAQ:ARYD) and Amicus Therapeutics (NASDAQ:FOLD) mutually agreed to terminate their previously announced business combination agreement due to existing market conditions, effective immediately. In September 2021, Amicus Therapeutics sai...

NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- ARYA Sciences Acquisition Corp IV (NASDAQ: ARYD) (“ARYA IV”), a publicly traded special purpose acquisition company sponsored by Perceptive Advisors announced today that, due to existing market conditions, it has mutually agreed with...

Amicus Therapeutics announced the formation of Caritas Therapeutics, consisting of Amicus' gene therapy portfolio. Amicus' stake will go from 100% to 36%, reducing the upside optionality of the gene therapy portfolio. The upside of the deal for Amicus is reduced costs and a clear ...